Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?
Cytokines and chemokines are undoubtedly involved in the pathogenesis of multiple sclerosis (MS). There are many reports that suggest a significant role for Interleukin-33 (IL-33) in the course of MS development, but it is not clear whether negative or positive. We therefore investigated plasma IL-3...
Gespeichert in:
| Veröffentlicht in: | Clinical neurology and neurosurgery 2021-07, Vol.206, p.106700-106700, Article 106700 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106700 |
|---|---|
| container_issue | |
| container_start_page | 106700 |
| container_title | Clinical neurology and neurosurgery |
| container_volume | 206 |
| creator | Mado, Hubert Adamczyk-Sowa, Monika Bartman, Wojciech Wierzbicki, Krzysztof Tadeusiak, Bartosz Sowa, Paweł |
| description | Cytokines and chemokines are undoubtedly involved in the pathogenesis of multiple sclerosis (MS). There are many reports that suggest a significant role for Interleukin-33 (IL-33) in the course of MS development, but it is not clear whether negative or positive. We therefore investigated plasma IL-33 levels in patients with relapsing-remitting MS (RRMS).
The study consisted of RRMS patients (n = 73) and healthy subjects (n = 54). Blood samples were taken from all and plasma IL-33 levels were then determined using an enzyme-linked immunosorbent assay method. Patients also underwent laboratory and imaging tests and their disability status was assessed.
Plasma IL-33 levels were marginally significantly higher in patients with RRMS (p = 0.07). Higher IL-33 levels are significantly associated with higher age (p = 0.01). There was also a statistically significant negative correlation between plasma IL-33 levels and the number of high signal intensity lesions in T2-weighted MRI (p = 0.03). After dividing the number of lesions into groups |
| doi_str_mv | 10.1016/j.clineuro.2021.106700 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2532246375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846721002298</els_id><sourcerecordid>2532246375</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-f3050c184e1320dcc266dc3d40bbe72e776479b3338d5e3fd8d34091164b07753</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EokPhFSpLbNhksGOPnawAVfyMVAkWsLYS-065g-ME25lq3ojHxCEtCzasbNnfuefqHEKuONtyxtXr49Z6DDDHcVuzmpdHpRl7RDa80XWlWtU8JhsmmKgaqfQFeZbSkTEmhGqekgshyxfT7Yb8-uK7NHR0HzJED_MPDJUQ1MMJPMVAI_huShhuqwgD5lxudJh9xskDTdZDHBOmLd0nipkGuO0yFumZ2jEu2gyO3mH-Ti2EHDtfkHga50TTOWUYilHCMaTFairSAqWVH9A76jB1PXrM5zfPyZND5xO8uD8vybcP779ef6puPn_cX7-7qayUMlcHwXbM8kYCFzVz1tZKOSucZH0PugatldRtL4Ro3A7EwTWuhNFyrmTPtN6JS_JqnTvF8ecMKZsBkwXvuwBlb1PvRF1LJf6gL_9Bj-McQ9luoVqui5kqlFopW6JKEQ5mijh08Ww4M0uX5mgeujRLl2btsgiv7sfP_QDur-yhvAK8XQEoeZwQokm2JGjBYQSbjRvxfx6_AZmXtk0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539177766</pqid></control><display><type>article</type><title>Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Mado, Hubert ; Adamczyk-Sowa, Monika ; Bartman, Wojciech ; Wierzbicki, Krzysztof ; Tadeusiak, Bartosz ; Sowa, Paweł</creator><creatorcontrib>Mado, Hubert ; Adamczyk-Sowa, Monika ; Bartman, Wojciech ; Wierzbicki, Krzysztof ; Tadeusiak, Bartosz ; Sowa, Paweł</creatorcontrib><description>Cytokines and chemokines are undoubtedly involved in the pathogenesis of multiple sclerosis (MS). There are many reports that suggest a significant role for Interleukin-33 (IL-33) in the course of MS development, but it is not clear whether negative or positive. We therefore investigated plasma IL-33 levels in patients with relapsing-remitting MS (RRMS).
The study consisted of RRMS patients (n = 73) and healthy subjects (n = 54). Blood samples were taken from all and plasma IL-33 levels were then determined using an enzyme-linked immunosorbent assay method. Patients also underwent laboratory and imaging tests and their disability status was assessed.
Plasma IL-33 levels were marginally significantly higher in patients with RRMS (p = 0.07). Higher IL-33 levels are significantly associated with higher age (p = 0.01). There was also a statistically significant negative correlation between plasma IL-33 levels and the number of high signal intensity lesions in T2-weighted MRI (p = 0.03). After dividing the number of lesions into groups < 9 and ≥ 9 T2-weighted lesions, the Student's t-test for unrelated variables showed a negative correlation, but not statistically significant (p = 0.22), while the Spearman's correlation showed a marginally significant correlation (p = 0.06) between IL-33 level and number of T2-weighted lesions. IL-33 was also shown to have a significant ability to differentiate RRMS patients from healthy subjects with a sensitivity of 99% and specificity of 70% (p = 0.00).
Patients with RRMS have elevated plasma IL-33 levels. In RRMS patients with mild disability, high plasma levels of IL-33 may have neuroprotective effects potentially by stimulating remyelination and/or suppressing autoimmune inflammation and damage. Further studies on this matter on a larger number of patients are needed.
•Plasma IL-33 levels are elevated in patients with mild RRMS.•Plasma IL-33 levels in mild RRMS are negatively correlated to the number of T2-hyperintense MRI lesions.•IL-33 in RRMS may show neuroprotective effects.</description><identifier>ISSN: 0303-8467</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2021.106700</identifier><identifier>PMID: 34030079</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Autoimmune diseases ; Biomarkers - blood ; Central nervous system ; Central Nervous System - pathology ; Chemokines ; Chronic obstructive pulmonary disease ; Cytokines ; Disease ; Enzyme-linked immunosorbent assay ; Female ; Hematology ; Humans ; IL-33 ; Immunology ; Inflammation ; Interleukin-33 ; Interleukin-33 - blood ; Lesions ; Magnetic resonance imaging ; Male ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - blood ; Multiple Sclerosis, Relapsing-Remitting - pathology ; Myelination ; Nervous system ; Neurology ; Neuroprotection ; Plasma ; Plasma levels ; Statistical analysis</subject><ispartof>Clinical neurology and neurosurgery, 2021-07, Vol.206, p.106700-106700, Article 106700</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</rights><rights>2021. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-f3050c184e1320dcc266dc3d40bbe72e776479b3338d5e3fd8d34091164b07753</citedby><cites>FETCH-LOGICAL-c444t-f3050c184e1320dcc266dc3d40bbe72e776479b3338d5e3fd8d34091164b07753</cites><orcidid>0000-0003-2271-615X ; 0000-0002-1610-036X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2539177766?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34030079$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mado, Hubert</creatorcontrib><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Bartman, Wojciech</creatorcontrib><creatorcontrib>Wierzbicki, Krzysztof</creatorcontrib><creatorcontrib>Tadeusiak, Bartosz</creatorcontrib><creatorcontrib>Sowa, Paweł</creatorcontrib><title>Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?</title><title>Clinical neurology and neurosurgery</title><addtitle>Clin Neurol Neurosurg</addtitle><description>Cytokines and chemokines are undoubtedly involved in the pathogenesis of multiple sclerosis (MS). There are many reports that suggest a significant role for Interleukin-33 (IL-33) in the course of MS development, but it is not clear whether negative or positive. We therefore investigated plasma IL-33 levels in patients with relapsing-remitting MS (RRMS).
The study consisted of RRMS patients (n = 73) and healthy subjects (n = 54). Blood samples were taken from all and plasma IL-33 levels were then determined using an enzyme-linked immunosorbent assay method. Patients also underwent laboratory and imaging tests and their disability status was assessed.
Plasma IL-33 levels were marginally significantly higher in patients with RRMS (p = 0.07). Higher IL-33 levels are significantly associated with higher age (p = 0.01). There was also a statistically significant negative correlation between plasma IL-33 levels and the number of high signal intensity lesions in T2-weighted MRI (p = 0.03). After dividing the number of lesions into groups < 9 and ≥ 9 T2-weighted lesions, the Student's t-test for unrelated variables showed a negative correlation, but not statistically significant (p = 0.22), while the Spearman's correlation showed a marginally significant correlation (p = 0.06) between IL-33 level and number of T2-weighted lesions. IL-33 was also shown to have a significant ability to differentiate RRMS patients from healthy subjects with a sensitivity of 99% and specificity of 70% (p = 0.00).
Patients with RRMS have elevated plasma IL-33 levels. In RRMS patients with mild disability, high plasma levels of IL-33 may have neuroprotective effects potentially by stimulating remyelination and/or suppressing autoimmune inflammation and damage. Further studies on this matter on a larger number of patients are needed.
•Plasma IL-33 levels are elevated in patients with mild RRMS.•Plasma IL-33 levels in mild RRMS are negatively correlated to the number of T2-hyperintense MRI lesions.•IL-33 in RRMS may show neuroprotective effects.</description><subject>Adult</subject><subject>Autoimmune diseases</subject><subject>Biomarkers - blood</subject><subject>Central nervous system</subject><subject>Central Nervous System - pathology</subject><subject>Chemokines</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Cytokines</subject><subject>Disease</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>IL-33</subject><subject>Immunology</subject><subject>Inflammation</subject><subject>Interleukin-33</subject><subject>Interleukin-33 - blood</subject><subject>Lesions</subject><subject>Magnetic resonance imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - blood</subject><subject>Multiple Sclerosis, Relapsing-Remitting - pathology</subject><subject>Myelination</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Neuroprotection</subject><subject>Plasma</subject><subject>Plasma levels</subject><subject>Statistical analysis</subject><issn>0303-8467</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc1u1DAUhS0EokPhFSpLbNhksGOPnawAVfyMVAkWsLYS-065g-ME25lq3ojHxCEtCzasbNnfuefqHEKuONtyxtXr49Z6DDDHcVuzmpdHpRl7RDa80XWlWtU8JhsmmKgaqfQFeZbSkTEmhGqekgshyxfT7Yb8-uK7NHR0HzJED_MPDJUQ1MMJPMVAI_huShhuqwgD5lxudJh9xskDTdZDHBOmLd0nipkGuO0yFumZ2jEu2gyO3mH-Ti2EHDtfkHga50TTOWUYilHCMaTFairSAqWVH9A76jB1PXrM5zfPyZND5xO8uD8vybcP779ef6puPn_cX7-7qayUMlcHwXbM8kYCFzVz1tZKOSucZH0PugatldRtL4Ro3A7EwTWuhNFyrmTPtN6JS_JqnTvF8ecMKZsBkwXvuwBlb1PvRF1LJf6gL_9Bj-McQ9luoVqui5kqlFopW6JKEQ5mijh08Ww4M0uX5mgeujRLl2btsgiv7sfP_QDur-yhvAK8XQEoeZwQokm2JGjBYQSbjRvxfx6_AZmXtk0</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Mado, Hubert</creator><creator>Adamczyk-Sowa, Monika</creator><creator>Bartman, Wojciech</creator><creator>Wierzbicki, Krzysztof</creator><creator>Tadeusiak, Bartosz</creator><creator>Sowa, Paweł</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2271-615X</orcidid><orcidid>https://orcid.org/0000-0002-1610-036X</orcidid></search><sort><creationdate>202107</creationdate><title>Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?</title><author>Mado, Hubert ; Adamczyk-Sowa, Monika ; Bartman, Wojciech ; Wierzbicki, Krzysztof ; Tadeusiak, Bartosz ; Sowa, Paweł</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-f3050c184e1320dcc266dc3d40bbe72e776479b3338d5e3fd8d34091164b07753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Autoimmune diseases</topic><topic>Biomarkers - blood</topic><topic>Central nervous system</topic><topic>Central Nervous System - pathology</topic><topic>Chemokines</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Cytokines</topic><topic>Disease</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>IL-33</topic><topic>Immunology</topic><topic>Inflammation</topic><topic>Interleukin-33</topic><topic>Interleukin-33 - blood</topic><topic>Lesions</topic><topic>Magnetic resonance imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - blood</topic><topic>Multiple Sclerosis, Relapsing-Remitting - pathology</topic><topic>Myelination</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Neuroprotection</topic><topic>Plasma</topic><topic>Plasma levels</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mado, Hubert</creatorcontrib><creatorcontrib>Adamczyk-Sowa, Monika</creatorcontrib><creatorcontrib>Bartman, Wojciech</creatorcontrib><creatorcontrib>Wierzbicki, Krzysztof</creatorcontrib><creatorcontrib>Tadeusiak, Bartosz</creatorcontrib><creatorcontrib>Sowa, Paweł</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mado, Hubert</au><au>Adamczyk-Sowa, Monika</au><au>Bartman, Wojciech</au><au>Wierzbicki, Krzysztof</au><au>Tadeusiak, Bartosz</au><au>Sowa, Paweł</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><addtitle>Clin Neurol Neurosurg</addtitle><date>2021-07</date><risdate>2021</risdate><volume>206</volume><spage>106700</spage><epage>106700</epage><pages>106700-106700</pages><artnum>106700</artnum><issn>0303-8467</issn><eissn>1872-6968</eissn><abstract>Cytokines and chemokines are undoubtedly involved in the pathogenesis of multiple sclerosis (MS). There are many reports that suggest a significant role for Interleukin-33 (IL-33) in the course of MS development, but it is not clear whether negative or positive. We therefore investigated plasma IL-33 levels in patients with relapsing-remitting MS (RRMS).
The study consisted of RRMS patients (n = 73) and healthy subjects (n = 54). Blood samples were taken from all and plasma IL-33 levels were then determined using an enzyme-linked immunosorbent assay method. Patients also underwent laboratory and imaging tests and their disability status was assessed.
Plasma IL-33 levels were marginally significantly higher in patients with RRMS (p = 0.07). Higher IL-33 levels are significantly associated with higher age (p = 0.01). There was also a statistically significant negative correlation between plasma IL-33 levels and the number of high signal intensity lesions in T2-weighted MRI (p = 0.03). After dividing the number of lesions into groups < 9 and ≥ 9 T2-weighted lesions, the Student's t-test for unrelated variables showed a negative correlation, but not statistically significant (p = 0.22), while the Spearman's correlation showed a marginally significant correlation (p = 0.06) between IL-33 level and number of T2-weighted lesions. IL-33 was also shown to have a significant ability to differentiate RRMS patients from healthy subjects with a sensitivity of 99% and specificity of 70% (p = 0.00).
Patients with RRMS have elevated plasma IL-33 levels. In RRMS patients with mild disability, high plasma levels of IL-33 may have neuroprotective effects potentially by stimulating remyelination and/or suppressing autoimmune inflammation and damage. Further studies on this matter on a larger number of patients are needed.
•Plasma IL-33 levels are elevated in patients with mild RRMS.•Plasma IL-33 levels in mild RRMS are negatively correlated to the number of T2-hyperintense MRI lesions.•IL-33 in RRMS may show neuroprotective effects.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34030079</pmid><doi>10.1016/j.clineuro.2021.106700</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-2271-615X</orcidid><orcidid>https://orcid.org/0000-0002-1610-036X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0303-8467 |
| ispartof | Clinical neurology and neurosurgery, 2021-07, Vol.206, p.106700-106700, Article 106700 |
| issn | 0303-8467 1872-6968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2532246375 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Adult Autoimmune diseases Biomarkers - blood Central nervous system Central Nervous System - pathology Chemokines Chronic obstructive pulmonary disease Cytokines Disease Enzyme-linked immunosorbent assay Female Hematology Humans IL-33 Immunology Inflammation Interleukin-33 Interleukin-33 - blood Lesions Magnetic resonance imaging Male Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - pathology Myelination Nervous system Neurology Neuroprotection Plasma Plasma levels Statistical analysis |
| title | Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Interleukin-33%20level%20in%20relapsing-remitting%20multiple%20sclerosis.%20Is%20it%20negatively%20correlated%20with%20central%20nervous%20system%20lesions%20in%20patients%20with%20mild%20disability?&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Mado,%20Hubert&rft.date=2021-07&rft.volume=206&rft.spage=106700&rft.epage=106700&rft.pages=106700-106700&rft.artnum=106700&rft.issn=0303-8467&rft.eissn=1872-6968&rft_id=info:doi/10.1016/j.clineuro.2021.106700&rft_dat=%3Cproquest_cross%3E2532246375%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539177766&rft_id=info:pmid/34030079&rft_els_id=S0303846721002298&rfr_iscdi=true |